Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

3(60.0%)

Phase 3

1(20.0%)

Phase 2

1(20.0%)

5Total

N/A(3)

Phase 3(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT07347275Phase 3Not Yet Recruiting

A Novel Extracorporeal Liver Support Therapy In ALCF and to Evaluate the Efficacy of DIALIVE 2.0, a Liver Dialysis Device.

Role: lead

NCT06890039Phase 2Not Yet Recruiting

A-TANGO Phase 2 Study

Role: lead

NCT03962608Not ApplicableWithdrawn

Safety and Tolerability of Yaq-001 in Patients With Non-Alcoholic Steatohepatitis

Role: lead

NCT03065699Not ApplicableCompleted

Safety and Performance Trial of DIALIVE Liver Dialysis Device in Acute On Chronic Liver Failure Patients

Role: lead

NCT03202498Not ApplicableTerminated

Safety and Tolerability of Yaq-001 in Patients With Cirrhosis

Role: lead

All 5 trials loaded